BALAXI PHARMA LTD
BALAXI · General/Diversified · NSE
₹27
Current Market Price
Fair Value (DCF)
₹41
Margin of Safety
+51.4%
Updated 1d ago
YieldIQ Score
68/100
Piotroski F-Score
4/9
Economic Moat
Narrow
Confidence
46%
ROE
—
Debt/Equity
0.24
WACC
11.1%
Market Cap
₹149 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
—
Return on capital employed
EV / EBITDA
7.6×
Enterprise multiple
Debt / EBITDA
2.6×
Leverage vs earnings
Interest Coverage
—
EBIT covers interest
Current Ratio
—
Short-term liquidity
Asset Turnover
0.94×
Revenue per ₹ of assets
Revenue CAGR (3Y)
1.6%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹26.94
Bear case
₹24.22
MoS -11.2%
Base case
₹40.8
MoS +34.0%
Bull case
₹52.9
MoS +49.1%
Ratio Trends
BALAXI · last 4 annual periods
ROE
10.8%
ROCE
11.7%
Operating Margin
—
Debt / Equity
0.23×
PE
63.7×
EV / EBITDA
49.2×
Historical Financials
BALAXI · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹231 Cr | ₹279 Cr | ₹336 Cr | ₹241 Cr | ₹293 Cr | +6.0% |
| EBITDA | — | ₹55.2 Cr | ₹59.2 Cr | ₹5.8 Cr | ₹33.5 Cr | -11.7% |
| EBIT | ₹44.3 Cr | ₹54.7 Cr | ₹57.4 Cr | ₹3.7 Cr | — | -46.3% |
| PAT | ₹38.1 Cr | ₹47.7 Cr | ₹46.0 Cr | ₹-2.4 Cr | ₹25.1 Cr | -10.0% |
| EPS (diluted) | ₹38.14 | ₹47.66 | ₹45.40 | ₹-2.31 | — | — |
| CFO | ₹0.0 Cr | ₹34.1 Cr | ₹6.1 Cr | ₹4.9 Cr | ₹-35.0 Cr | — |
| CapEx | — | — | — | — | ₹-21.8 Cr | — |
| FCF | — | — | — | — | ₹-56.8 Cr | — |
| Total Assets | — | ₹176 Cr | ₹240 Cr | ₹258 Cr | ₹310 Cr | +15.2% |
| Total Debt | — | — | ₹10.8 Cr | ₹17.7 Cr | ₹53.4 Cr | +49.3% |
| Shareholders' Equity | — | — | ₹183 Cr | ₹201 Cr | ₹232 Cr | +6.1% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
BALAXI vs 3 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| LYKALABS LYKALABS | — | — | Pending | 7.7% | — |
| HALEOSLABS HALEOSLABS | — | — | Pending | 9.5% | — |
| TAKE TAKE | — | — | Pending | — | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for BALAXI in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. BALAXI PHARMA LTD (BALAXI.NS) trades at 26.94 vs a model fair value of 40.80, a gap of 51.4%. Piotroski F-score: 4/9. Moat label: Narrow....
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of BALAXI →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for BALAXI →
Compare
Head-to-head with peers
Compare BALAXI side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse BALAXINow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.